摘要
类风湿关节炎是一种以滑膜炎症为基本病理表现的自身免疫性疾病,临床常以对称性多关节疼痛、肿胀为主要症状,甚者还会引发肺间质纤维化和冠状动脉疾病等关节外表现和合并症,严重影响患者的生活质量。中医药治疗类风湿关节炎具有多通路、多靶点、多成分及毒副反应少的特点,在类风湿关节炎治疗中发挥着重要的作用。近年,许多研究已经证实中药单体及中药复方可以通过调控磷脂酰肌醇3-激酶(phosphatidylinositol3 kinase,PI3K)/蛋白激酶B(protein kinase B,Akt)信号通路控制炎症,减少血管新生,诱导滑膜成纤维细胞凋亡,抑制其增殖、侵袭、迁移,发挥治疗类风湿关节炎的作用。基于此,该文概述了PI3K/Akt信号通路及其对类风湿关节炎的作用,总结中医药通过调控PI3K/Akt信号通路治疗类风湿关节炎的研究进展,以期为类风湿关节炎的治疗及新药开发提供理论依据。
Rheumatoid arthritis(RA)is an autoimmune disease with the basic pathological manifestation of synovial inflammation.Symmetric poly-articular pain and swelling are the main symptoms in clinical practice,and even extra-articular manifestations and comorbidities such as interstitial fibrosis and coronary artery disease are triggered,which seriously affect the quality of life of patients.Traditional Chinese medicine(TCM)has achieved good clinical efficacy in the prevention and treatment of RA with the advantages of multi-pathway,multi-target,multicomponent,and less toxic side effects,and plays an important role in the treatment of RA.Recently,many studies have demonstrated that Chinese medicine monomers and Chinese herbal compound can control inflammation,reduce angiogenesis,induce apoptosis of synovial fibroblasts,and inhibit their proliferation,invasion and migration by regulating the PI3K/Akt signaling pathway,so as to play a key role in the treatment of RA.For this reason,the article summarizes current knowledge regarding the PI3K/Akt signaling pathway and its role in RA,as well as summarizes the current research progress of TCM in the treatment of RA by regulating the PI3K/Akt signaling pathway.The aim of this review is to provide theoretical bases for the prevention and treatment of RA and the development of new drugs.
作者
程伟刚
李浩林
杨娟娟
金芳梅
阚丽丽
陶鹏飞
王振东
柏倩
苏小军
王海东
CHENG Weigang;LI Haolin;YANG Juanjuan;JIN Fangmei;KAN Lili;TAO Pengfei;WANG Zhendong;BAI Qian;SU Xiaojun;WANG Haidong(Gansu University of Traditional Chinese Medicine,Lanzhou 730000 Gansu,China;Center of Rheumatic Osteopathy,Gansu Province Hospital of Traditional Chinese Medicine,Lanzhou 730000 Gansu,China)
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2024年第5期756-764,共9页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
国家自然科学基金项目(82260880)
国家中医优势专科建设项目(甘卫中医函[2023]63号)
国家中医药管理局高水平中医药重点学科建设项目(国中医药人教函[2023]85号)
甘肃省中医药项目([2021]572号)。